ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 23, 2018--
BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology
company developing and commercializing products addressing degenerative
diseases, today announced that Russell Skibsted, Chief Financial
Officer, will be presenting at the Noble Capital Markets 14th
Annual Investor Conference on Monday, January 29, 2018 at 4:00pm ET, at
Hotel Fort Lauderdale.
A webcast of Mr. Skibsted’s presentation at this conference will be
available at noble.mediasite.com.
A replay of the presentation will also be available at the Events
and Presentations section of the BioTime website.
About BioTime, Inc.
BioTime is a late-stage clinical biotechnology company focused on
developing and commercializing products addressing degenerative
diseases. The Company’s current clinical programs are targeting three
primary sectors, aesthetics, ophthalmology and cell and drug delivery.
Its clinical programs are based on two platform technologies:
pluripotent cells, which can become any type of cell in the human body,
and cell/drug delivery. Renevia®, a cell delivery product,
met its primary endpoint in an EU pivotal clinical trial for the
treatment of facial lipoatrophy in HIV patients earlier this year.
Submission for approval of Renevia® in the EU is expected to
be early 2018, with possible approval and commercial launch in 2018.
There were no device related serious adverse events reported to date.
OpRegen®, a retinal pigment epithelium transplant therapy, is
in a Phase I/IIa multicenter trial for the treatment of dry age-related
macular degeneration, the leading cause of blindness in developing
countries. There were no related serious adverse events reported to
date. BioTime also has significant equity holdings in two publicly
traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST)
and OncoCyte Corporation (NYSE American: OCX), and a private company,
AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotime.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180123005620/en/
Source: BioTime, Inc.
David Nakasone, 510-871-4188
JQA Partners, Inc.
Jules Abraham, 917-885-7378